Related by context. All words. (Click for frequent words.) 79 HRQOL 76 HRQoL 75 HRQL 72 subscales 70 EQ 5D 69 symptom severity 69 subscale scores 68 Health Assessment Questionnaire 68 QOL 67 PANSS 66 UPDRS 66 EORTC QLQ C# 66 IPSS 66 SGRQ 65 psychosocial functioning 65 Montgomery Åsberg Depression 65 HDRS 65 Rating Scale MADRS 64 Montgomery Asberg Depression 64 IBDQ 64 WOMAC 64 neurocognitive function 64 Functional Assessment 64 depressive symptoms 64 psychometric properties 63 ADAS cog 63 Physical Component 63 MADRS score 63 International Prostate Symptom 63 DAS# [002] 63 HAM D# 63 BMI z 62 Brief Psychiatric 62 NIH CPSI 62 subscores 62 comorbidity 62 HAQ DI 62 NYHA functional class 62 HAMD 62 Negative Syndrome 62 Psoriasis Area 62 liver histology 62 T2DM 62 clinically meaningful improvements 62 somatic symptoms 61 Visual Analog Scale 61 depressive symptomatology 61 euthymic patients 61 CORE OM 61 MMSE score 61 Secondary endpoints 61 MADRS 61 Unified Parkinson Disease 61 WOMAC pain 61 biochemical recurrence 61 Status Scale EDSS 61 univariate analyzes 61 IIEF 61 HADS 61 euthymic 61 ADAS Cog 61 Alzheimer Disease Assessment 61 Neuropsychiatric Inventory 61 Disease Activity 60 clinically meaningful improvement 60 point Likert scale 60 YMRS 60 Rating Scale BPRS 60 Scale EDSS 60 LUTS 60 PSQI 60 Depressive symptoms 60 DLQI 60 depressive symptom 60 MetS 60 multivariate analyzes 60 psychiatric comorbidity 60 adenotonsillectomy 60 Scale PANSS 60 Incontinence Impact Questionnaire 60 MMSE 60 Rating Scale 60 Symptom Checklist 60 psychiatric morbidity 60 Mental Component 60 ADCS CGIC 60 subscore 60 Score DAS 60 Outcomes Study 60 affective disorders 60 QIDS SR 60 Oswestry Disability Index 59 PANSS total 59 BPRS 59 pain subscale 59 covariate 59 comorbid 59 preoperatively 59 SF #v# 59 SELENA SLEDAI 59 VFQ 59 PsA 59 Expanded Disability Status 59 Global Impression CGI 59 Rating Scale UPDRS 59 psychosocial variables 59 Scale Cognitive Subscale 59 erection hardness 59 urinary symptoms 59 Logistic regression analysis 59 WOMAC scores 59 alexithymia 59 IRLS 59 posttransplant 59 FACIT Fatigue 59 BILAG 58 Epworth Sleepiness Scale 58 Hamilton Rating Scale 58 Score IPSS 58 Global Impression 58 Neuropsychiatric Inventory NPI 58 CNS LS 58 lipid profiles 58 LVEF 58 cognitive affective 58 Index CDAI 58 Distress Scale 58 ADCS ADL 58 dyspnoea 58 Primary endpoints 58 Scale cognitive subscale 58 fasting insulin 58 P = .# 58 multivariable analysis 58 Pain Intensity 58 NIS LL 58 prognostic factors 58 Score TOS 58 subclinical atherosclerosis 58 endometrial thickness 58 posttreatment 57 enthesitis 57 comorbid anxiety 57 histologic 57 bivariate analysis 57 convergent validity 57 sociodemographic variables 57 BPH symptom 57 CDAI 57 radical prostatectomy RP 57 comorbid conditions 57 PCWP 57 State Examination MMSE 57 comorbid depression 57 logistic regression analyzes 57 carotid IMT 57 Secondary efficacy endpoints 57 MMSE scores 57 Visual Analogue Scale VAS 57 premorbid 57 EDSS score 57 Pain Rating Scale 57 APACHE II 57 virologic response 57 function subscale 57 Seattle Angina Questionnaire 57 mTSS 57 % CI #.#-#.# [006] 57 Comorbidity 57 nondepressed 57 exploratory endpoints 57 HAQ 57 NIHSS 57 Main Outcome Measures 57 p = .# [002] 57 subthreshold depression 57 PANSS scores 57 neurocognitive functioning 57 logistic regression model 57 Score DAS# 57 RLS symptoms 57 HbA 1c 57 preoperative PSA 57 androgen deprivation 57 metabolic parameters 57 symptomatic VTE 57 PSADT 57 sd = 57 plasma folate 57 mRS 57 EDSS 57 WOMAC TM 56 Secondary endpoints included 56 logistic regression analysis 56 % Confidence Interval 56 IPAH 56 Symptom severity 56 Fibromyalgia Impact Questionnaire 56 diabetes mellitus DM 56 F FDG PET 56 multivariable adjusted 56 prostate cancer CaP 56 Logistic regression 56 Depression Scale 56 albumin excretion rate 56 haematologic 56 chronicity 56 interrater reliability 56 OAB symptoms 56 serum lipid levels 56 Sociodemographic 56 dyslipidaemia 56 HbA 1c levels 56 erythrocyte sedimentation rate 56 pelvic lymphadenectomy 56 endoscopic remission 56 PSA nadir 56 Abnormal Involuntary Movement 56 Hamilton Anxiety Scale 56 univariate analysis 56 UPDRS motor 56 comorbidities 56 posttest 56 HbA1c levels 56 affective psychoses 56 psychiatric comorbidities 56 secondary efficacy endpoint 56 affective psychosis 56 untreated psychosis 56 meta regression 56 hydroxyvitamin D levels 56 Subgroup analyzes 56 virological response 56 DAS# CRP 56 CC genotype 56 APOE genotype 56 multivariate logistic regression 56 nasal symptom 56 NNT = 56 CIMZIA TM certolizumab pegol 55 tertile 55 microalbuminuria 55 antioxidant supplementation 55 myocardial viability 55 extrapyramidal symptoms 55 Likert scale 55 primary aldosteronism 55 ANCOVA 55 autonomic dysfunction 55 Structured Clinical 55 hemodynamic parameters 55 Mini Mental 55 Depression Rating Scale 55 baseline HbA1c 55 Crohn Disease Activity 55 Secondary endpoints include 55 interobserver 55 SLEDAI 55 PHQ 9 55 subclinical hypothyroidism 55 nasal obstruction 55 shorter telomere length 55 tumor histology 55 non menstrual pelvic 55 fasting plasma glucose 55 CI #.#-#.# [001] 55 systolic function 55 = #.#-#.# 55 urodynamic parameters 55 amnestic MCI 55 % CI #.#-#.# [007] 55 allele frequencies 55 erectile function 55 FACIT 55 CI -#.# 55 confidence intervals CIs 55 nonpsychotic 55 pCR 55 glycosylated hemoglobin levels 55 echocardiographic parameters 55 HOMA IR 55 sociodemographic 55 intraobserver 55 Ejection Fraction 55 apnea hypopnea index 55 Postoperative 55 overactive bladder symptoms 55 prognostic variables 55 undetectable HBV DNA 55 prognostic factor 55 reflux symptoms 55 androgen suppression 55 EBRT 55 systolic BP 55 Treatment Outcome 55 nonfatal MI 55 oxycodone CR 55 multivariate Cox 55 Natalizumab 55 TNSS 55 Subgroup analysis 55 Index FSFI 55 systolic hypertension 55 Preoperatively 55 intact parathyroid hormone 55 sociodemographic characteristics 55 lowest tertile 55 glycosylated hemoglobin HbA1c 55 oncologic outcomes 55 Erectile Function 55 somatization disorder 55 Geriatric Depression 55 undergoing coronary angiography 55 Cystic Fibrosis Questionnaire Revised 55 GERD symptom 55 perioperative complications 55 % CI #.#-#.# [003] 55 DAS# scores 55 biopsy Gleason 55 RECIST Response Evaluation Criteria 55 suicide attempters 55 euthyroid 55 bulimia nervosa 55 postoperative AF 55 Glasgow Coma Scale 55 Sjögren syndrome 54 schizophrenia schizoaffective disorder 54 comorbid psychiatric disorders 54 -#.# ± [002] 54 IKDC 54 poststroke 54 postoperative mortality 54 rhinoconjunctivitis 54 BPS IC 54 carotid stenosis 54 adjunctive ABILIFY 54 covariates 54 Kaplan Meier analysis 54 Erectile Function IIEF 54 Lower Limb 54 schizophreniform disorder 54 Insulin sensitivity 54 cognitive domains 54 postoperative complication 54 clinically meaningful reductions 54 bosentan 54 hip BMD 54 % CI #.#-#.# [008] 54 dysthymia 54 pulmonary capillary wedge 54 tertiles 54 ALND 54 nonobese 54 Fecal Incontinence 54 EDSS scores 54 thyrotropin levels 54 Global Impression Severity 54 syndromal 54 subsyndromal 54 dyspnea 54 T1DM 54 obstructive CAD 54 cardiac autonomic 54 Hopkins Symptom Checklist 54 adrenal function 54 HbA1C levels 54 morbidity mortality 54 abdominal pain abdominal discomfort 54 prospectively defined 54 salivary cortisol 54 interobserver reliability 54 psychiatric outpatients 54 Flu Cy 54 SGAs 54 femoral neck BMD 54 histological subtype 54 ECOG 54 Charlson comorbidity index 54 methotrexate monotherapy 54 secondary endpoint 54 neuropsychological 54 IRLS score 54 CTEPH 54 intima media thickness 54 antidepressant efficacy 54 Severity Index PASI 54 pT2 54 serum folate concentrations 54 CFQ R 54 pramipexole 54 immunostaining 54 p = #.# [002] 54 atherothrombotic disease 54 serum concentrations 54 cardiometabolic risk 54 daytime somnolence 54 lipid parameters 54 carotid intima media 54 Socioeconomic status 54 dyspareunia 54 scintigraphic 54 metabolic syndrome MetS 54 lumbar spine BMD 54 cognitive function 54 prespecified secondary 54 neuropsychiatric symptoms 54 daytime sleepiness 54 monoclonal gammopathy 54 hypogonadal 54 adiponectin concentrations 54 radiographic progression 54 5 HTTLPR 54 confidence interval #.#-#.# 54 tic severity 54 HAM D 54 interpersonal psychotherapy 54 Univariate analysis 54 Y BOCS 54 semiquantitative 54 hemodynamics 54 intraclass correlation coefficients 54 randomized controlled trials RCTs 54 hypoglycaemic episodes 54 nondiabetic patients 54 Visual Analog 54 prognostic significance 54 beta blocker therapy 54 nonalcoholic steatohepatitis NASH 54 plain radiographs 54 polyarticular 54 Severity MSCS score 54 sociodemographic factors 53 ECOG PS 53 transvaginal sonography 53 actigraphy 53 NIHSS score 53 Index HAQ DI 53 CRp 53 inflammatory markers 53 CHADS 53 vasomotor 53 nonmetastatic prostate cancer 53 cerebral perfusion 53 Depression Inventory 53 FDG uptake 53 chromium picolinate supplementation 53 proliferative diabetic retinopathy 53 mesalamine granules 53 LV ejection fraction 53 mucosal healing 53 nighttime awakenings 53 alanine aminotransferase ALT 53 symptomatology 53 generalized anxiety disorder GAD 53 clinicopathological 53 bladder carcinoma 53 tiotropium 53 adalimumab 53 vasomotor symptoms 53 progression TTP 53 postmenopausal osteoporotic women 53 STN stimulation 53 hypochondriasis 53 SSRI citalopram 53 angiographically 53 acetabular dysplasia 53 dyssynchrony 53 atherogenic dyslipidemia 53 postoperative radiotherapy 53 Cronbach alpha 53 QRS duration 53 prevalences 53 perinatal outcomes 53 psychopathological symptoms 53 ALSFRS R 53 macroalbuminuria 53 plasma cortisol 53 CR nPR 53 pT3 53 Multivariate analyzes 53 #OHD 53 fasting triglyceride levels 53 postintervention 53 RAPAFLO R 53 subjective sleepiness 53 psychosocial 53 aripiprazole 53 echocardiographic 53 Major Depressive Disorder 53 multivariate adjustment 53 somatic symptom 53 ALS Functional 53 aromatase inhibitor therapy 53 aMCI 53 seminal vesicle invasion 53 LV dysfunction 53 HNSCC 53 emotional lability 53 prospective multicenter study 53 prospective longitudinal 53 periprocedural MI 53 confidence interval CI 53 HSCT 53 liver transplant recipients 53 univariate 53 CPAP adherence 53 glycemia 53 timepoints 53 clinicopathological features 53 retest reliability 53 morphometric vertebral fractures 53 serologically active patients 53 hypertensives 53 prucalopride 53 serum testosterone 53 adenoma recurrence 53 highest tertile 53 TT genotype 53 allergic rhinitis AR 53 psychoeducation 53 hsCRP levels 53 Beck Anxiety Inventory 53 mRNA expression 53 HIV HCV coinfected 53 Ankylosing Spondylitis 53 conditional logistic regression 53 rheumatoid factor 53 serum estradiol 53 desvenlafaxine succinate 53 T2D 53 KOOS 53 estimated glomerular filtration 53 atrophic gastritis 53 multivariable analyzes 53 urothelial carcinoma 53 apolipoproteins 53 menopausal symptom 53 Main Outcome Measure 53 rs# [002] 53 hyperglycaemia 53 Female Sexual Function 53 kidney allograft 53 #F FDG PET 53 Apgar scores 53 Scale EDSS score 53 preoperative 53 hematological parameters 53 daytime alertness 53 TEAEs 53 symptom checklist 53 mammographic density 53 coadministration 53 hippocampal volume 53 androgen deficiency 53 anemia hemoglobin 53 graft dysfunction 53 ADHD symptoms 53 Depressive Symptoms 53 histologically confirmed 53 underwent resection 53 Cystatin C 53 postoperatively 53 prognostic indicators 53 immunohistochemical staining 53 HRCT 53 % CI #.#-#.# [005] 52 DAS# remission 52 sUA 52 apolipoprotein B 52 CANCIDAS 52 PCa 52 CCyR 52 antihypertensive therapy 52 virologic responses 52 cytogenetic response 52 adjunctive placebo 52 depressive disorders 52 cranial irradiation 52 Chronic Illness Therapy 52 left ventricular LV 52 Hemodynamic 52 FDG PET 52 postdischarge 52 hippocampal atrophy 52 Histologic 52 Comorbid 52 inflammatory biomarkers 52 Visual Analogue Scale 52 serum PTH 52 urinary albumin excretion 52 Comorbidities 52 statistically significant improvement 52 triiodothyronine 52 coronary stenosis 52 CR CRu 52 DSM IV Axis 52 tipranavir r 52 Severity Scale 52 lymphadenectomy 52 plasma lipids 52 nonoperative treatment 52 Dyspnea 52 REYATAZ r arm 52 glycosylated hemoglobin 52 subscale 52 Endothelial function 52 McGill Pain Questionnaire 52 leukocyte counts 52 preoperative chemotherapy 52 dose atorvastatin 52 Baseline characteristics 52 fractional anisotropy 52 tryptophan depletion 52 Ocular Surface Disease 52 solifenacin 52 spirometric 52 SSc 52 bivariate analyzes 52 left ventricular diastolic 52 logistic regression 52 FEV ^ sub 52 glycated hemoglobin levels 52 rotigotine 52 median PFS 52 diastolic pressures 52 AGILECT ® 52 secondary efficacy endpoints 52 postoperative 52 Mania Rating Scale 52 odds ratios ORs 52 Scale CNS 52 IBS symptoms 52 Eur J Endocrinol 52 Alzheimer Disease Cooperative 52 hepatic lesions 52 Meta analyzes 52 State Trait Anxiety 52 β blockers 52 ATACAND 52 glomerular filtration rate 52 #.#ng/ml 52 POAG 52 relapsing multiple sclerosis 52 progesterone receptor PR 52 elevated ALT 52 UPDRS scores 52 Reynolds Risk Score 52 placebo controlled clinical 52 lymph node metastasis 52 Multivariate analysis 52 operable breast cancer 52 CDAI score 52 extensive metabolizers 52 somatic complaints 52 MGUS 52 Cognitive behavioral 52 Kruskal Wallis test 52 knee osteoarthritis OA 52 #q# deletion syndrome 52 glycated hemoglobin 52 familial aggregation 52 Numeric Rating Scale 52 multivessel disease 52 Mean Symptom Complex 52 hepatocellular carcinomas 52 clinically localized prostate 52 Oncotype DX Recurrence Score 52 systolic diastolic 52 postoperative morbidity 52 somatoform disorders 52 adrenalectomy 52 hsCRP 52 inotropic 52 Recurrence Score 52 elevated triglyceride levels 52 baseline FEV 52 CIMZIA ™ 52 SSRI SNRI 52 prospective cohort 52 Solid Tumours 52 spondyloarthritis 52 normotensive 52 INVEGA ® 52 anthropometric measures 52 antiarrhythmic drug 52 CIBIC plus 52 extracapsular extension 52 neuropsychological assessment 52 colorectal adenoma 52 Response Evaluation Criteria 52 CRQ 52 physiologic parameters 52 neurodevelopmental outcome 52 abdominal adiposity 52 amnestic mild cognitive impairment 52 decrements 52 Bonferroni correction 52 KRAS status 52 analgesic efficacy 52 HbA1C 52 vertebral fracture 52 chronic prostatitis chronic 52 CYP#D# genotype 52 SLNB 52 coronary calcification 52 psoriatic arthritis PsA 52 graft patency 52 metabolite concentrations 52 STRIDE PD 52 FOLPI 52 TRANSFORMS 52 Patency 52 undergoing radical prostatectomy 52 prostate cancer PCa 52 clinical endpoints 52 parkinsonian symptoms 52 transient elastography 52 radical cystectomy 52 gadolinium enhanced 52 glycated hemoglobin HbA1c 52 predictive validity 52 hemodialysis patients 52 demonstrated clinically meaningful 52 elevated creatinine 52 dysthymic disorder 52 Pearson correlation coefficients 52 ejaculatory function 52 pharmacodynamic PD 52 Satisfaction Questionnaire 52 creatinine ratio 52 GH deficiency 52 thromboembolic 52 achieved statistical significance 52 bronchial hyperresponsiveness 52 T1a 52 p = .# [001] 52 Cardiotoxicity 52 unpaired t 52 PaO 2 52 ADHD RS 52 hypertension diabetes mellitus 52 elevated IOP 52 airflow obstruction 52 neurocognitive impairment 52 multivariate regression analysis 52 neuropsychological functioning 52 Physical Function 52 rFSH 52 glucose homeostasis 52 preoperative diagnosis 52 pain catastrophizing 52 ± SD 52 overnight polysomnography 52 multivariate analysis 52 left ventricular systolic 52 nonsignificant 52 atheroma volume 52 hyperhomocysteinemia 52 Negative Symptoms 52 SCr 52 histological subtypes 52 urinary incontinence UI 52 Neuropsychological 52 achieved ACR# 52 psychopathology 52 coronary artery calcium 52 hemoglobin A1C 52 transthoracic echocardiography 51 tolvaptan 51 haemodynamic 51 thromboembolic events 51 George Respiratory Questionnaire 51 Visual acuity 51 histologic subtype 51 thromboembolism 51 teriflunomide 51 palliation 51 mL/min/#.# m 2 51 blood Phe 51 contrast echocardiography 51 diabetes dyslipidemia 51 atrioventricular block 51 lymphopenia 51 perimenopausal women 51 Child Behavior Checklist 51 QTc 51 bacterial prostatitis 51 Regression analyzes 51 serum cortisol 51 CLBP 51 Pearson correlation coefficient 51 Thrombolysis 51 renal function 51 neurologic impairment 51 urinary tract symptoms 51 tocilizumab 51 hydroxyvitamin D 51 dimensional echocardiography 51 dichotomized 51 artery stenosis 51 Multivariate logistic regression 51 endometrial carcinoma 51 rs# [004] 51 asthma exacerbation 51 RENAL 51 mcg QD 51 NSTEMI 51 neurodevelopmental outcomes 51 anti JCV antibodies 51 hepatic fibrosis 51 serum vitamin D 51 mg BID 51 platelet reactivity 51 EuroSCORE 51 QTc interval 51 MR spectroscopy 51 esomeprazole 51 laboratory abnormalities 51 arterial oxygen saturation 51 neurological abnormalities 51 probands 51 fasting plasma 51 multiple logistic regression 51 SYNTAX 51 subclinical hyperthyroidism 51 lymphocyte count 51 incontinence episodes 51 AST ALT 51 OGTT 51 inflammatory rheumatic 51 RoACTEMRA 51 nephron sparing surgery 51 moderate renal impairment 51 GH deficient 51 CIBIC + 51 outcomes 51 percutaneous vertebroplasty 51 Suicidal ideation 51 quetiapine XR 51 locoregional 51 electrophysiologic 51 glatiramer acetate 51 Clinician Administered PTSD 51 Complications Trial 51 aminotransferases 51 mg BID dose 51 hemoglobin A1c HbA1c 51 HBeAg 51 urinary N telopeptide 51 neoadjuvant chemotherapy 51 proband 51 retinal thickness 51 Symptom 51 histopathological 51 hematologic parameters 51 serum IGF 51 alanine aminotransferase 51 serum parathyroid hormone 51 Relapsing Remitting Multiple Sclerosis 51 serum prostate 51 Medication adherence 51 tirofiban 51 tissue oxygenation 51 PASI scores 51 polyp recurrence 51 perioperative morbidity 51 unfavorable prognostic 51 Functional Outcomes 51 fasting glucose 51 ischemic cardiomyopathy 51 IV NSCLC 51 MACCE 51 rs# [001] 51 Antiviral Therapy 51 intravesical therapy 51 blood Phe levels 51 neurocognitive deficits 51 NLX P# 51 diameter stenosis 51 mycophenolate mofetil 51 prospectively stratified 51 KCCQ 51 epithelial ovarian cancer 51 PLMs 51 acromegalic patients 51 serum phosphate 51 subclinical cardiovascular disease 51 postprocedure 51 ragweed allergic 51 methacholine challenge 51 RE LY ® 51 unipolar depression 51 sonographic findings 51 μmol L 51 nondiabetic 51 clinicopathologic 51 DMARD 51 certolizumab 51 biochemical relapse 51 cortical atrophy 51 ejaculatory control 51 systolic dysfunction 51 bioavailable testosterone 51 IL#B 51 SDQ 51 unfavorable cytogenetics 51 DSM IV SCID 51 postoperative pulmonary 51 #OHD levels 51 IBS C 51 paricalcitol 51 SYNTAX trial 51 Generalized Anxiety Disorder 51 Index WOMAC 51 Dysmenorrhea 51 hemoglobin A1c levels 51 Heritability 51 n = 51 phonophobia 51 fasting glucose levels 51 cardiovascular morbidity 51 lipid levels 51 NMIBC 51 intracranial hypertension 51 inhibin 51 Free Survival PFS 51 nomograms 51 Symptom Severity 51 ER CHOP 51 Health Questionnaire PHQ 51 serum phosphate levels 51 plus methotrexate 51 ≥ 51 bivariate 51 serum ALT 51 plasma triglycerides 51 pericardial effusion 51 Univariate 51 baseline LDH 51 Doxil ® 51 mIU L 51 Group ECOG 51 trough FEV1 51 ANOVA 51 vesicoureteral reflux 51 p = 51 subsyndromal depression 51 macrovascular disease 51 underwent liver transplantation 51 DPNP 51 perioperative mortality 51 QT intervals 51 Symptom Scale 51 postinjury 51 Multiple logistic regression 51 aMCI precursor 51 Skin sterol 51 stage IIIb IV 51 retrospective cohort 51 statistically significant differences 51 Predictors 51 comorbid psychiatric 51 neurocognitive 51 BEXXAR Therapeutic Regimen 51 Posttraumatic stress disorder 51 plus MTX 51 aminotransferase levels 51 FOLFOX4 51 IELT 51 placebo p = 51 nonadherence 51 co morbidities 51 antidiabetic medication 51 MDRD equation 51 venous thromboembolic disease 51 atopic 51 Decitabine 51 Stent thrombosis 51 multivariable Cox 51 nausea photophobia 51 hemodynamic measurements 51 CIN2 + 51 chronic thromboembolic pulmonary 51 concomitant medications 51 recurrent VTE 51 guanfacine extended release 51 adenomatous polyps 51 logistic regression models 51 Interrater reliability 51 NATRECOR R 51 nodal metastases 51 etanercept 51 generalized estimating 51 ACR# [002] 51 rosuvastatin #mg 51 thromboprophylaxis 51 arterial thickening 51 axillary lymph node 51 fructosamine